Get started
Harmony Biosciences Holdings, Inc.Harmony Biosciences Holdings, Inc.Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HRMY chart


Full chart

HRMY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.99 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
16.23
Basic EPS (TTM)
2.15 USD
Net income (FY)
‪128.85 M‬ USD
Revenue (FY)
‪582.02 M‬ USD
Shares float
‪40.49 M‬
Beta (1Y)
1.08

Employees


Employees (FY)
246
Change (1Y)
+46 +23.00%
Revenue / Employee (1Y)
‪2.37 M‬ USD
Net income / Employee (1Y)
‪523.79 K‬ USD

About Harmony Biosciences Holdings, Inc.


Sector
Health Technology
CEO
Jeffrey M. Dayno
Headquarters
Plymouth Meeting
Website
harmonybiosciences.com
Founded
2017
FIGI
BBG00WBPG4C2
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HRMY news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of HRMY is 34.06 USD — it has increased by 1.95% in the past 24 hours. Watch Harmony Biosciences Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Harmony Biosciences Holdings, Inc. stocks are traded under the ticker HRMY.
HRMY stock has risen by 7.67% compared to the previous week, the month change is a 5.37% rise, over the last year Harmony Biosciences Holdings, Inc. has showed a 3.90% increase.
We've gathered analysts' opinions on Harmony Biosciences Holdings, Inc. future price: according to them, HRMY price has a max estimate of 75.00 USD and a min estimate of 31.00 USD. Watch HRMY chart and read a more detailed Harmony Biosciences Holdings, Inc. stock forecast: see what analysts think of Harmony Biosciences Holdings, Inc. and suggest that you do with its stocks.
HRMY reached its all-time high on Dec 5, 2022 with the price of 62.09 USD, and its all-time low was 18.61 USD and was reached on Oct 13, 2023. View more price dynamics on HRMY chart.
See other stocks reaching their highest and lowest prices.
HRMY stock is 3.61% volatile and has beta coefficient of 1.08. Track Harmony Biosciences Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Harmony Biosciences Holdings, Inc. there?
Today Harmony Biosciences Holdings, Inc. has the market capitalization of ‪1.99 B‬, it has increased by 4.15% over the last week.
Yes, you can track Harmony Biosciences Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Harmony Biosciences Holdings, Inc. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
HRMY earnings for the last quarter are 0.79 USD per share, whereas the estimation was 0.66 USD resulting in a 18.82% surprise. The estimated earnings for the next quarter are 0.68 USD per share. See more details about Harmony Biosciences Holdings, Inc. earnings.
Harmony Biosciences Holdings, Inc. revenue for the last quarter amounts to ‪186.04 M‬ USD, despite the estimated figure of ‪184.07 M‬ USD. In the next quarter, revenue is expected to reach ‪198.60 M‬ USD.
HRMY net income for the last quarter is ‪46.09 M‬ USD, while the quarter before that showed ‪11.59 M‬ USD of net income which accounts for 297.66% change. Track more Harmony Biosciences Holdings, Inc. financial stats to get the full picture.
No, HRMY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 246.00 employees. See our rating of the largest employees — is Harmony Biosciences Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Harmony Biosciences Holdings, Inc. EBITDA is ‪199.56 M‬ USD, and current EBITDA margin is 37.18%. See more stats in Harmony Biosciences Holdings, Inc. financial statements.
Like other stocks, HRMY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Harmony Biosciences Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Harmony Biosciences Holdings, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Harmony Biosciences Holdings, Inc. stock shows the sell signal. See more of Harmony Biosciences Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.